Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KD1903
- Development stage
- Preclinical
- Lead developer
- Kyungdong Pharmaceutical
- Modality
- Small Molecules
01
Overview
KD1903 is an investigational small molecule drug candidate developed by Kyung Dong Pharmaceutical for the treatment of hypertension. It is categorized as an Incrementally Modified Drug (IMD), a South Korean regulatory designation for drugs that offer improvements in safety, efficacy, or administration over existing therapies (such as new salts, formulations, or combinations). As of early 2021, KD1903 was in the preclinical stage of development within the cardiovascular therapeutic area. Specific details regarding its molecular target or active pharmaceutical ingredient have not been publicly disclosed by the company.
Beyond the preview
Go deeper on KD1903.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KD1903.